Bourgeon Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bourgeon Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,500	Closed	-$4.28K	–	401
2023 Q4	$4.28K	Hold	7,500	–	–	﹤0.01%	276
2023 Q3	$7.8K	Hold	7,500	–	–	﹤0.01%	242
2023 Q2	$10.6K	Sell	7,500 -1,500	-17%	-$2.15K	﹤0.01%	249
2023 Q1	$14.3K	Sell	9,000 -8,500	-49%	-$15.4K	﹤0.01%	214
2022 Q4	$25.6K	Sell	17,500 -3,000	-15%	-$8.76K	0.01%	186
2022 Q3	$88K	Hold	20,500	–	–	0.02%	119
2022 Q2	$80K	Hold	20,500	–	–	0.02%	122
2022 Q1	$98K	Hold	20,500	–	–	0.02%	122
2021 Q4	$75K	Buy	20,500 +1,750	+9%	+$9.34K	0.02%	136
2021 Q3	$150K	Buy	18,750 +18,250	+3,650%	+$180K	0.03%	115
2021 Q2	$6K	Sell	500 -500	-50%	-$5.02K	﹤0.01%	248
2021 Q1	$9K	Buy	+1,000	New	+$10.4K	﹤0.01%	234

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bourgeon Capital Management's VIRX Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2024, closing a stake of 7,500 shares — an estimated $4.28K sold.

Bourgeon Capital Management first reported a position in VIRX in Q1 2021 and held it in 12 quarters. The position peaked at $150K in Q3 2021. 40 funds tracked by Wall St. Rank hold VIRX as of Q1 2024.

Bourgeon Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 7,500 Viracta Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.28K.
Bourgeon Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
Bourgeon Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $150K in Q3 2021.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.